Please assess the completion status of the following clinical trial:

Trial Title: Bifocal Lenses In Nearsighted Kids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 7 to 11 years, inclusive, at baseline examination~* -0.75 to -5.00 D, inclusive, spherical component, cycloplegic autorefraction~* ≤1.00 DC, cycloplegic autorefraction~* ≥ 2.00 D difference between the sphere components of the two eyes (anisometropia), cycloplegic autorefraction~* 0.1 logMAR or better best-corrected visual acuity in each eye~* 0.1 logMAR or better visual acuity OU distance and near with a +2.50 D add contact lens~* +2.50 D add lens provides adequate fit with respect to movement and centration~Exclusion Criteria:~* Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.)~* Systemic disease that may affect vision, vision development, or contact lens wear (eg, diabetes, Down syndrome, etc.)~* Previous gas permeable, soft bifocal, or orthokeratology contact lens wear or bifocal/PAL spectacle wear (longer than 1 month of wear)~* Previous or current participation in myopia control studies~* Chronic use of medications that may affect immunity, such as oral or ophthalmic corticosteroids for ocular or systemic diseases~* Issues that may interfere with the ability to participate over the next 3 years

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Biofinity (Type: ACTIVE_COMPARATOR): Soft spherical contact lens
- Biofinity Multifocal D +1.50 add (Type: EXPERIMENTAL): The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power
- Biofinity Multifocal D +2.50 add (Type: EXPERIMENTAL): The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power

Based on this trial design, predict the completion outcome and termination type (if applicable).